Search results | inflammation


Inflammatory Partnering

Inflammatory Partnering report provides understanding and access to the inflammatory partnering deals and agreements entered into by the worlds leading healthcare companies.


Genmab: Partnering activity 2009-2014

Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment.

Isis Pharmaceuticals: Partnering activity 2009-2014

Isis Pharmaceuticals, a leader in antisense drug discovery, has emerged as a top 50 big biotech company with its business strategy.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Isis Pharmaceuticals: So many partnerships, so little time

Isis Pharmaceuticals is an antisense drug discovery technology company developing therapies for a number of serious diseases.

M&A rumors for buyout of Achillion Pharmaceuticals by big pharma

UBS analyst Andrew Peters suggested that a recent takeover big in the biotech space of California-based InterMune, Inc.  by Roche was the harbinger of more M&A rumors to come.

Top 15 most partnered therapeutic trends in pharma industry

Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list

Galapagos – Rapidly taking identified targets through to clinical development

Galapagos is a clinical stage biotechnology company headquartered in Belgium discovering and developing candidates to phase I/II development.

Sun Pharmaceutical: Fast becoming the branded generic company of choice

Sun Pharmaceutical is a global specialty pharmaceutical company serving over 40 different markets with its brands and branded generics.


AstraZeneca is a top pharmaceutical company based in London, United Kingdom

Novo Nordisk

Novo Nordisk is a top pharmaceutical/ healthcare company based in Bagsvaerd, Denmark


Sorry, your search returned no results.


Celgene and Abide enter into a pharma alliance for inflammation drugs

Abide Therapeutic has entered into a strategic pharma alliance collaboration with Celgene Corporation to discover and develop new drugs in inflammation and immunology.

Array biopharma partners with Celgene for inflammation pathway

Array BioPharma partners with Celgene Corporation for an Array-invented preclinical development program targeting a novel inflammation pathway

Celgene pharma partnering with Concert for cancer and inflammation therapies

Concert Pharmaceuticals has entered into a pharma partnering collaboration with Celgene , a big pharma corporation, directed towards deuterium-modified compounds targeting cancer and inflammation.

Ziarco in pharma partnering deal with Pfizer for anti-inflammation and anti-allergic drugs

Ziarco has entered into a pharma partnering agreement with Pfizer  for the exclusive worldwide rights to commercialize a portfolio of clinical, preclinical and research anti-inflammatory and anti-allergic assets

BioDuro and AstraZeneca expand collaboration to optimize discovery research for respiratory and inflammation

BioDuro will provide integrated research services in the areas of discovery chemistry, discovery biology, ADMET*, and DMPK** services, to help enhance internal drug discovery and shorten development timelines.

Takeda has made a financing investment in BioMotiv

Takeda has made a strategic financing investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations.

Collaboration agreement for INV102 (nadolol) and INV104 (zafirlukast)

Invion announce a collaboration with 3M Drug Delivery Systems for the development of its inhaled respiratory drug franchise.

Probiodrug signs biotech deals with AstraZeneca for CDK9 program

Probiodrug AG to sign biotech deals and announced the transfer of its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to bigpharma AstraZeneca

Crescendo Biologics raise $28 million in series A financing

Crescendo Biologics has raised £17.5m ($28m) in a Series A financing.

Proposed IPO financing for $86.25 million

GlycoMimetics has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering financing of shares of its common stock